This week in therapeutics

Indication

Target/marker/pathway

Summary

Licensing status

Publication and contact information

Infectious disease

HCV; HIV/AIDS

Type I interferon receptor

Mouse studies suggest neutralizing interferon (IFN) receptor signaling could help treat persistent HIV or HCV infections. In mice infected with a persistent strain of lymphocytic choriomeningitis virus (LCMV), expression of IFN, proinflammatory cytokines and immunosuppressive factors was greater than that in mice infected with an acute LCMV strain. In mice with persistent LCMV infection, prophylactic or therapeutic treatment with an anti-IFN receptor antibody initially increased viral loads but decreased or eliminated the virus during the chronic phase of infection compared with isotype control treatment. Next steps include testing the strategy in human viral infections, including HIV.

SciBX 6(17); doi:10.1038/scibx.2013.417
Published online May 2, 2013

Patent and licensing status unavailable for findings from first study

Provisional patent application filed for findings from second study; available for licensing

Teijaro, J.R. et al. Science;
published online April 12, 2013;
doi:10.1126/science.1235214
Contact: Michael B.A. Oldstone,
The Scripps Research Institute,
La Jolla, Calif.
e-mail:
mbaobo@scripps.edu

Wilson, E.B. et al. Science;
published online April 12, 2013;
doi:10.1126/science.1235208
Contact: David G. Brooks, University of California Los Angeles, Calif.
e-mail:
dbrooks@microbio.ucla.edu